系统性硬化症的生物标志物。
Biomarkers in systemic sclerosis.
机构信息
Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA 19107-15541, USA.
出版信息
Biomark Med. 2010 Feb;4(1):133-47. doi: 10.2217/bmm.09.79.
Abstract
Systemic sclerosis is an autoimmune inflammatory disorder of unknown etiologycharacterized b y pronounced fibroproliferative alterations in the microvasculature, and frequent cellular and humoral immunity abnormalities, culminating in a severe and often progressive fibrotic process. Numerous biomarkers reflecting the three main pathogenetic mechanisms in systemic sclerosis have been described; however, aside from several disease-specific autoantibodies, other biomarkers have not been thoroughly validated and require further study. Thus, there is an unmet need for validated biomarkers for diagnosis, disease classification, and evaluation of organ involvement and therapeutic response in systemic sclerosis.
摘要
系统性硬化症是一种病因不明的自身免疫性炎症性疾病，其特征为微血管明显的纤维增生性改变，以及频繁的细胞和体液免疫异常，最终导致严重且常进展的纤维化过程。已经描述了许多反映系统性硬化症三种主要发病机制的生物标志物；然而，除了几种疾病特异性自身抗体外，其他生物标志物尚未得到充分验证，需要进一步研究。因此，需要有经过验证的生物标志物来诊断、分类疾病，评估器官受累和治疗反应。
相似文献
1
Biomarkers in systemic sclerosis.
Biomark Med. 2010 Feb;4(1):133-47. doi: 10.2217/bmm.09.79.
2
An update on biomarker discovery and use in systemic sclerosis.
Expert Rev Mol Diagn. 2017 Sep;17(9):823-833. doi: 10.1080/14737159.2017.1356722. Epub 2017 Jul 25.
3
[Pulmonary fibrosis and systemic sclerosis].
Pneumoftiziologia. 1997 Oct-Dec;46(4):267-83.
4
Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers.
Respirology. 2019 Jul;24(7):675-683. doi: 10.1111/resp.13500. Epub 2019 Feb 12.
5
[Progressive systemic sclerosis].
Ryoikibetsu Shokogun Shirizu. 1994(4):537-9.
6
A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways.
Front Immunol. 2025 Apr 16;16:1551911. doi: 10.3389/fimmu.2025.1551911. eCollection 2025.
7
Immunology of systemic sclerosis.
Front Biosci. 2005 May 1;10:1707-19. doi: 10.2741/1654.
8
The lung in systemic sclerosis.
J Clin Rheumatol. 2005 Feb;11(1):40-6. doi: 10.1097/01.rhu.0000152147.38706.db.
9
Decrease in DL,CO in systemic sclerosis correlates with acceleration of DTPA clearance.
Eur Respir J. 1999 Sep;14(3):728-9. doi: 10.1034/j.1399-3003.1999.14c42.x.
10
Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Arthritis Rheumatol. 2020 Mar;72(3):465-476. doi: 10.1002/art.41153. Epub 2020 Jan 28.
引用本文的文献
1
Identification of serum exosome proteins in systemic sclerosis with interstitial lung disease by aptamer proteomics.
Arthritis Res Ther. 2025 Jul 10;27(1):146. doi: 10.1186/s13075-025-03595-8.
2
Comparative transcriptomic analysis validates iPSC derived in-vitro progressive fibrosis model as a screening tool for drug discovery and development in systemic sclerosis.
Sci Rep. 2024 Oct 18;14(1):24428. doi: 10.1038/s41598-024-74610-2.
3
Polyneuropathy in systemic sclerosis: exploring the causes and biomarkers.
Front Med (Lausanne). 2024 Aug 2;11:1412706. doi: 10.3389/fmed.2024.1412706. eCollection 2024.
4
Perspective to precision medicine in scleroderma.
Front Immunol. 2024 Jan 18;14:1298665. doi: 10.3389/fimmu.2023.1298665. eCollection 2023.
5
Serum biomarkers in patients with hand-arm vibration injury and in controls.
Sci Rep. 2024 Feb 1;14(1):2719. doi: 10.1038/s41598-024-52782-1.
6
Oral Submucous Fibrosis and Scleroderma: A Review of the Etiopathogenesis, Clinicopathological Correlation, and Management Aspects.
Cureus. 2023 Aug 31;15(8):e44502. doi: 10.7759/cureus.44502. eCollection 2023 Aug.
7
Efficacy of Fractional CO Laser for Improvement of Limited Mouth Opening in Systemic Sclerosis.
J Cutan Aesthet Surg. 2022 Oct-Dec;15(4):387-393. doi: 10.4103/JCAS.JCAS_29_21.
8
Aptamer proteomics of serum exosomes from patients with Primary Raynaud's and patients with Raynaud's at risk of evolving into Systemic Sclerosis.
PLoS One. 2022 Dec 22;17(12):e0279461. doi: 10.1371/journal.pone.0279461. eCollection 2022.
9
The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.
Int J Mol Sci. 2022 Sep 5;23(17):10150. doi: 10.3390/ijms231710150.
10
Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases.
Front Pharmacol. 2021 Oct 12;12:754851. doi: 10.3389/fphar.2021.754851. eCollection 2021.
本文引用的文献
1
A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.
J Invest Dermatol. 2010 Mar;130(3):694-705. doi: 10.1038/jid.2009.318. Epub 2009 Oct 8.
2
Non-invasive biomarkers in pulmonary fibrosis.
Respirology. 2009 Aug;14(6):788-95. doi: 10.1111/j.1440-1843.2009.01600.x.
3
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.
Eur Respir J. 2010 Jan;35(1):95-104. doi: 10.1183/09031936.00074309. Epub 2009 Jul 30.
4
Pulmonary complications: one of the most challenging complications of systemic sclerosis.
Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii40-4. doi: 10.1093/rheumatology/kep109.
5
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. doi: 10.1093/rheumatology/kep107.
6
Transforming growth factor-beta in systemic sclerosis (scleroderma).
Front Biosci (Schol Ed). 2009 Jun 1;1(1):226-35. doi: 10.2741/s22.
7
Scleroderma.
N Engl J Med. 2009 May 7;360(19):1989-2003. doi: 10.1056/NEJMra0806188.
8
Anti-topoisomerase I autoantibodies in systemic sclerosis.
Autoimmun Rev. 2009 Jul;8(8):692-6. doi: 10.1016/j.autrev.2009.02.018. Epub 2009 Feb 13.
9
Transforming growth factor beta as a therapeutic target in systemic sclerosis.
Nat Rev Rheumatol. 2009 Apr;5(4):200-6. doi: 10.1038/nrrheum.2009.26.
10
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
J Rheumatol. 2009 Apr;36(4):773-80. doi: 10.3899/jrheum.080633. Epub 2009 Mar 13.
Zotero 插件